Related Experiment Videos
Safety profile of cefodizime
1Abteilung Nephrologie, Medizinische Klinik, Universität Heidelberg, Germany.
Infection
|January 1, 1992
Summary
Cefodizime (CDZ) demonstrates excellent safety in animal studies and clinical trials, showing better renal tolerance than other cephalosporins. This antibiotic has a favorable risk-benefit profile for patient use.
Area of Science:
- Pharmacology
- Toxicology
- Clinical Medicine
Background:
- Cefodizime (CDZ) is a cephalosporin antibiotic.
- Previous studies indicated potential safety concerns with cephalosporins.
Purpose of the Study:
- To evaluate the safety and tolerability of Cefodizime (CDZ).
- To compare the safety profile of CDZ with other cephalosporins in clinical settings.
Main Methods:
- Animal toxicology studies were conducted.
- Clinical trials involving 6,299 patients treated with CDZ and 1,225 patients receiving comparator cephalosporins were analyzed.
Main Results:
- Animal studies showed no safety concerns, with better renal tolerance than other cephalosporins and no adverse effects on reproductive parameters.
- Clinical trials indicated similar mortality rates (1.6% for CDZ vs. 1.75% for comparators) and a lower incidence of adverse drug reactions (ADRs) for CDZ (3.06% vs. 3.64%).
- ADRs were primarily gastrointestinal or allergic, with no established causal link to patient deaths. CDZ did not affect platelet count/function, coagulation, or vitamin K metabolism.
Conclusions:
- Cefodizime (CDZ) exhibits a favorable safety profile based on animal toxicology and extensive clinical trial data.
- CDZ demonstrates superior renal tolerance compared to other cephalosporins and does not adversely impact reproductive health.
- The overall risk-benefit ratio for Cefodizime (CDZ) is considered favorable.